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Abstract
Summary: Detecting significant associations between genetic variants and disease may prove par-
ticularly challenging when the variants are rare in the population and/or act together with other
variants to cause the disease. We have developed a statistical framework named Mutation
Enrichment Gene set Analysis of Variants (MEGA-V) that specifically detects the enrichments of
genetic alterations within a process in a cohort of interest. By focusing on the mutations of several
genes contributing to the same function rather than on those affecting a single gene, MEGA-V in-
creases the power to detect statistically significant associations.
Availability and Implementation: MEGA-V is available at https://github.com/ciccalab/MEGA
Contact: francesca.ciccarelli@kcl.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Despite the large amount of data from genome-wide association studies,
still a considerable fraction of genetic diseases lacks significant associ-
ations with causative variants. Different reasons account for the missing
heritability, including the disease-causative role of rare variants, the cumu-
lative effect of multiple variants to the disease phenotype, and/or the alter-
ations of different genes perturbing the same biological process. In all
these cases the detection of significant associations is challenging because
commonly used approaches lack statistical power. To solve this, some
methods collapse variants within a genomic region thus increasing the
overall signal (Lee et al., 2014; Pan et al., 2014; Wu et al., 2011).
However, these methods are designed to detect associations of few vari-
ants or single genes but not of multiple genes or biological functions.
Here, we present MEGA-V (Mutation Enrichment Gene set Analysis
of Variants) a statistical framework to identify biological processes
that are significantly over mutated in specific cohort of patients.
MEGA-V systematically aggregates genetic variants into pre-defined
gene sets and then identifies those gene sets with significant over-
representations of variants in the cohort of interest. The founding
principle of MEGA-V is similar to that of gene set analysis (GSA)
used to identify functionally related genes that show significant differ-
ences between biological states or phenotypes (de Leeuw et al., 2016;
Subramanian et al., 2005). Starting from the mutation counts in a co-
hort of samples, MEGA-V applies a GSA-like approach to detect sig-
nificantly altered processes, without any prior additional measure of
association between the variants and the phenotype of interest.
2 Methods
The purpose of MEGA-V is to identify gene sets that show a signifi-
cantly higher number of variants in a cohort of interest (cohort A, Fig.
1). A gene set is defined as a group of genes Xk ¼ {g1,. . ., gx} that share
common features, such as biological processes from curated databases,
or genes associated to the same disease (Fig. 1A). In addition to prede-
fined gene sets, MEGA-V requires the list of variants in each gene g of
the gene set Xk for each individual ai of cohort A¼ {a1,. . ., ay} (Fig.
1A). Variants are also predefined by the user and can be damaging
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mutations as well as other types of genetic alterations. Once the input
files are provided, the cumulative variant count Nkai within each gene
set Xk is computed for each individual ai in the cohort:
Nkai ¼
X
g2Xk
Mkai ;g
where Mkai ;g is the number of variants in gene g of the gene set Xk for
individual ai. The corresponding distribution of variant counts D
k
A
for the gene set Xk (Fig. 1B) is derived as:
DkA ¼ Nkai ; . . . ;Nkay
n o
To identify the variant gene sets in cohort A, two approaches can be
applied. In the first approach, a cohort B¼ {b1,. . ., bz} is used to com-
pare each distribution of variant counts DkA to the corresponding distri-
bution DkB ¼ Nkb ; . . . ;Nkbz
n o
(Fig. 1C), using Wilcoxon rank-sum test
or Kolmogorov–Smirnov test according to the type of data. If multiple
gene sets are tested, the resultingP-values are corrected for multiple test-
ing (Benjamini and Hochberg, 1995). When the sample size of the two
cohorts differs substantially, a bootstrapping procedure (random sam-
pling with replacement) can be applied, where the larger cohort is ran-
domly down-sampled to the size of the smaller cohort for 1000 times.
At each iteration, the distributions of variants within each gene set are
compared between the two cohorts and the proportion of significant en-
richments (P-value<0.05) over the total comparisons is calculated. In
the second approach, no control cohort is used and for each gene setXk
the total number of observed variants in cohort AOkA:
OkA ¼
X
DkA
is compared with the expected number of variants EkA:
EkA ¼
X
DkS
where S indicates the s-th out of 1000 Monte Carlo permutations, where
the total number of variants in cohort A is randomly distributed without
overlap across all genes. The empirical P-value for each gene set Xk is
measured as the fractionOkA that is greater or equal thanE
k
A (Fig. 1D).
3 Performance assessment
To assess the performance of MEGA-V in detecting enriched gene
sets, we set up a simulation study using two cohorts A and B each
consisting of 100 individuals. Each individual carried 5267 muta-
tions randomly assigned across 5267 unique genes of 186 biological
pathways (Subramanian et al., 2005). We simulated five conditions
where one additional mutation was randomly added in one of the
186 gene sets of 20, 40, 60, 80, 100 individuals of cohort A, respect-
ively, for a total of 930 simulations. In each simulation, we run
MEGA-V, ranked the 186 gene sets according to their P-values, and
derived the corresponding receiver operating characteristic (ROC)
curve (Supplementary Data). The average ROC curves in each con-
dition show that MEGA-V performed better as compared to ran-
domly ranked gene sets (Supplementary Fig. S1).
4 Implementation
MEGA-V is implemented as a R application and is freely available on
Github to be run locally or through a shiny web interface. MEGA-V
requires two input files, one for the gene sets and one for the list of
variants in cohort A. If cohort B is used for comparison, the associated
list of variants is also required. Pre-processed gene sets of biological
pathways (Subramanian et al., 2005) and diseases (Cereda et al.,
2016) are provided. Alternatively, the user can define customised gene
sets as a tab-separated file with one row per gene set specifying the
gene set name and the gene symbols. The variant list is a tab separated
file, with the gene symbols in the first column and the number of vari-
ants in each patient in the remaining columns. The results of the stat-
istical analysis are summarised in a text file reporting, for each gene
set, the results of the applied statistics (Wilcoxon rank-sum test,
Kolmogorov–Smirnov, or Monte Carlo permutations).
5 Conclusions
MEGA-V provides a statistical framework to test associations be-
tween any type of perturbed biological processes and disease. For
example, using MEGA-V, we have identified significantly mutated
immune gene sets in individuals with multiple colorectal cancers
(Cereda et al., 2016).
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Fig. 1. MEGA-V uses the lists of gene sets and variants in cohort A (A) to derive
the cumulative counts of variants in each gene set (B) and identify the enriched
gene sets using a comparison cohort B (C) or Monte Carlo permutations (D)
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